Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Clarus Therapeutics Holdings, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-21Dec-31-20Dec-31-19
   10-K10-KS-1
Revenues  14.06.40.0
            Revenue growth  119.1%  
Cost of goods sold  2.78.70.0
Gross profit  11.2-2.30.0
            Gross margin  80.5%-36.4% 
Selling, general and administrative   [+]47.342.514.8
Research and development  3.62.43.1
Other operating expenses  -15.9-81.7-23.8
EBITDA   [+]-23.834.55.9
            EBITDA margin  -170.6%541.8% 
Depreciation and amortization  0.00.00.0
EBIT   [+]-23.834.55.9
            EBIT margin  -170.8%541.6% 
Non-recurring items   66.3 
Interest expense, net   [+]15.915.423.8
Other income (expense), net   [+]-0.951.5-23.8
Pre-tax income  -40.64.3-41.7
Income taxes  0.00.00.0
            Tax rate  0.0%0.0%0.0%
Net income  -40.2-10.3-41.7
            Net margin  -288.1%-162.3% 
   
Basic EPS  ($5.72) ($20.54)
Diluted EPS   [+]($5.72)($1.21)($20.54)
   
Shares outstanding (basic)  7.0 0.9
Shares outstanding (diluted)   [+]7.08.50.9
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy